Initiative of clinical single‐cell biomedicine in clinical and translational medicine

With rapid developments of single‐cell sequencing and multi/trans‐omics, clinical single‐cell biomedicine is a new and emergent discipline to integrate single‐cell molecular and clinical phenomes and uncover new disease‐specific diagnoses and therapy. The journal of Clinical and Translational Medicine (CTM) launches the first CTM initiative of clinical single‐cell biomedicine (cscBioMed) to promote the discovery and development of single‐cell‐based biology and medicine, speed the translation from single‐cell biology into clinical application, and improve early diagnosis and therapy for human diseases. The cscBioMed initiative is speeding translational processes from circulating single‐cell RNA sequencing into routine measures in clinical biochemistry of haematology, from spatial transcriptomics into single‐cell pathology, and from single‐cell‐based biomarkers and targets into clinical diagnostics and target drugs. With a clear goal, we expect that cscBioMed will benefit human health by establishing a clinical single‐cell dynamic monitoring and early predicting system and by improving diagnosis and treatment.